Back to Search Start Over

Slan+monocytes and macrophages mediate CD20-dependent b-cell lymphoma elimination via ADCC and ADCP

Authors :
Federica Calzetti
Marco A. Cassatella
Claudio Agostinelli
Cristina Tecchio
Alessandra Micheletti
Luisa Lorenzi
Sara Costa
Giuseppe Rossi
Fabio Facchetti
Giulia Finotti
Piera Balzarini
Alessandra Tucci
Alberto Zamò
Stefano Pileri
Giuseppe Todeschini
Stefano Calza
William Vermi
Silvia Lonardi
Mattia Bugatti
Lara Furlani
Vermi, William
Micheletti, Alessandra
Finotti, Giulia
Tecchio, Cristina
Calzetti, Federica
Costa, Sara
Bugatti, Mattia
Calza, Stefano
Agostinelli, Claudio
Pileri, Stefano
Balzarini, Piera
Tucci, Alessandra
Rossi, Giuseppe
Furlani, Lara
Todeschini, Giuseppe
Zamó, Alberto
Facchetti, Fabio
Lorenzi, Luisa
Lonardi, Silvia
Cassatella, Marco A.
Publication Year :
2018

Abstract

Terminal tissue differentiation and function of slan+ monocytes in cancer is largely unexplored. Our recent studies demonstrated that slan+ monocytes differentiate into a distinct subset of dendritic cells (DC) in human tonsils and that slan+ cells colonize metastatic carcinoma-draining lymph nodes. Herein, we report by retrospective analysis of multi-institutional cohorts that slan+ cells infiltrate various types of non-Hodgkin lymphomas (NHL), particularly the diffuse large B-cell lymphoma (DLBCL) group, including the most aggressive, nodal and extranodal, forms. Nodal slan+ cells displayed features of either immature DC or macrophages, in the latter case ingesting tumor cells and apoptotic bodies. We also found in patients with DLBCL that peripheral blood slan+ monocytes, but not CD14+ monocytes, increased in number and displayed highly efficient rituximab-mediated antibody-dependent cellular cytotoxicity, almost equivalent to that exerted by NK cells. Notably, slan+ monocytes cultured in conditioned medium from nodal DLBCL (DCM) acquired a macrophage-like phenotype, retained CD16 expression, and became very efficient in rituximab-mediated antibody-dependent cellular phagocytosis (ADCP). Macrophages derived from DCM-treated CD14+ monocytes performed very efficient rituximab-mediated ADCP, however, using different FcγRs from those used by slan+ macrophages. Our observations shed new light on the complexity of the immune microenvironment of DLBCL and demonstrate plasticity of slan+ monocytes homing to cancer tissues. Altogether, data identify slan+ monocytes and macrophages as prominent effectors of antibody-mediated tumor cell targeting in patients with DLBCL. Significance: slan+ monocytes differentiate into macrophages that function as prominent effectors of antibody-mediated tumor cell targeting in lymphoma. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/13/3544/F1.large.jpg. Cancer Res; 78(13); 3544–59. ©2018 AACR.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....7d170ea018921e124c73aa6d401c090f